Jci_page_head_homepage_01 Jci_page_head_homepage_02
Mei Dong, Tam How, Kellye C. Kirkbride, Kelly J. Gordon, Jason D. Lee, Nadine Hempel, Patrick Kelly, Benjamin J. Moeller, Jeffrey R. Marks, Gerard C. Blobe
Published in Volume 117, Issue 1
J Clin Invest. 2007; 117(1):206–217 doi:10.1172/JCI29293
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 2
Progressive loss of TβRIII protein expression during mammary carcinogenesis.

(A) Representative IHC analysis of TβRIII expression (original magnification, ×40) in normal breast ductal cells, in different grades of DCIS, and in lymph node–negative (node neg) and –positive (node pos) IDC. Insets depict staining of entire tissue core (original magnification, ×10). Immunoreactivity for TβRIII was scored as 0–5 and categorized as low (0–1), medium (2–3), or high (4–5). Note the absence of TβRIII staining in IDC and high-grade DCIS (arrows) versus presence of staining in normal ducts and normal-appearing ducts adjacent to the DCIS lesion (arrowhead). (B) Summary of IHC results, with percentages shown. Dis met, distant metastasis. **P < 0.01, 2-tailed Fisher’s exact probability. (C) Patient-matched normal and invasive breast cancer IHC TβRIII scores. (D) Patient-matched DCIS and invasive breast cancer IHC TβRIII scores.